Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 6/2011

01-12-2011 | Review Article

Biological aspects of angiogenesis in multiple myeloma

Authors: Eléonore Otjacques, Marilène Binsfeld, Agnes Noel, Yves Beguin, Didier Cataldo, Jo Caers

Published in: International Journal of Hematology | Issue 6/2011

Login to get access

Abstract

Multiple myeloma (MM) is a hematological malignancy characterized by the aberrant expansion of malignant plasma cells within the bone marrow (BM). One of the hallmarks of this disease is the close interaction between myeloma cells and neighboring cells within the BM. Angiogenesis, through the activation of endothelial cells, plays an essential role in MM biology. In the current review, we describe the angiogenesis process in MM by identifying the interacting cells, the pro- and anti-angiogenic cytokines modulated, and the extracellular matrix degrading proteases liable to participate in the pathophysiology. Finally, we highlight the impact of hypoxia (through hypoxia-inducible factor-1) and constitutive activation of nuclear factor-κB in this tumor-induced neo-vascularization.
Literature
1.
Bray F, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38(1):99–166.PubMedCrossRef
2.
Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134(6):573–89.PubMedCrossRef
3.
Caers J, et al. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer. 2008;95(3):301–13.PubMed
4.
Mattioli M, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 2005;24(15):2461–73.PubMedCrossRef
5.
Kyle RA, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–9.PubMedCrossRef
6.
7.
8.
Rajkumar SV, et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999;13(3):469–72.PubMedCrossRef
9.
Vacca A, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87(3):503–8.PubMedCrossRef
10.
11.
Asosingh K, et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood. 2004;103(8):3131–7.PubMedCrossRef
12.
Perez-Atayde AR, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150(3):815–21.PubMed
13.
Sezer O, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000;79(10):574–7.PubMedCrossRef
14.
Rajkumar SV, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6(8):3111–6.PubMed
15.
Rajkumar SV, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8(7):2210–6.PubMed
16.
Alexandrakis MG, et al. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol. 2004;57(8):856–60.PubMedCrossRef
17.
Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009;19(5):329–37.PubMedCrossRef
18.
Kumar S, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004;104(4):1159–65.PubMedCrossRef
19.
20.
Pour L, et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol. 2010;89(4):385–9.PubMedCrossRef
21.
Fujii R, Yaccoby S, Epstein J. Control of myeloma growth with the anti-angiogenic agent endostatin. Blood. 2002;96:360a.
22.
Urbanska-Rys H, Robak T. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment. Mediators Inflamm. 2003;12(4):229–35.PubMedCrossRef
23.
De Raeve H, et al. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol. 2004;19(3):935–50.PubMed
24.
Ribatti D. The discovery of endothelial progenitor cells. An historical review. Leuk Res. 2007;31(4):439–44.PubMedCrossRef
25.
Vacca A, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003;102(9):3340–8.PubMedCrossRef
26.
Asahara T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–7.PubMedCrossRef
27.
Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest. 2000;105(1):17–9.PubMedCrossRef
28.
Suda T, Takakura N, Oike Y. Hematopoiesis and angiogenesis. Int J Hematol. 2000;71(2):99–107.PubMed
29.
Lyden D, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7(11):1194–201.PubMedCrossRef
30.
Yin AH, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90(12):5002–12.PubMed
31.
Miraglia S, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997;90(12):5013–21.PubMed
32.
Zhang H, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005;105(8):3286–94.PubMedCrossRef
33.
Dominici M, et al. Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical–biological features. Leukemia. 2001;15(1):171–6.PubMedCrossRef
34.
Wang X, Zhang Z, Yao C. Angiogenic activity of mesenchymal stem cells in multiple myeloma. Cancer Invest. 2011;29(1):37–41.PubMedCrossRef
35.
Scavelli C, et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene. 2008;27(5):663–74.PubMedCrossRef
36.
Caers J, et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia. 2007;21(7):1580–4.PubMedCrossRef
37.
Dankbar B, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor–stromal cell interactions in multiple myeloma. Blood. 2000;95(8):2630–6.PubMed
38.
Barille S, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood. 1997;90(4):1649–55.PubMed
39.
Urashima M, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997;90(2):754–65.PubMed
40.
Borset M, et al. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood. 1996;88(10):3998–4004.PubMed
41.
Hose D, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114(1):128–43.PubMedCrossRef
42.
Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777–94.PubMedCrossRef
43.
Vacca A, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;88(2):176–85.PubMed
44.
Podar K, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98(2):428–35.PubMedCrossRef
45.
Uchiyama H, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82(12):3712–20.PubMed
46.
Chauhan D, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87(3):1104–12.PubMed
47.
Kim I, et al. Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines. Br J Haematol. 1994;87(3):483–93.PubMedCrossRef
48.
Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene. 2006;25(31):4257–66.PubMedCrossRef
49.
Birchmeier C, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–25.PubMedCrossRef
50.
Maulik G, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002;13(1):41–59.PubMedCrossRef
51.
Hose D, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009;113(18):4331–40.PubMedCrossRef
52.
Seidel C, et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood. 1998;91(3):806–12.PubMed
53.
Derksen PW, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia. 2003;17(4):764–74.PubMedCrossRef
54.
Andersen NF, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 2005;128(2):210–7.PubMedCrossRef
55.
Alexandrakis MG, et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol. 2003;72(4):229–33.PubMedCrossRef
56.
Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–65.PubMedCrossRef
57.
Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993;73(1):161–95.PubMed
58.
Ribatti D, et al. In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J Cell Sci. 1999;112(Pt 23):4213–21.PubMed
59.
Vacca A, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93(9):3064–73.PubMed
60.
Bisping G, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood. 2003;101(7):2775–83.PubMedCrossRef
61.
Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor–host interface. Semin Cell Dev Biol. 2008;19(1):52–60.PubMedCrossRef
62.
Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3(6):422–33.PubMedCrossRef
63.
Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005;65(10):3967–79.PubMedCrossRef
64.
Monteiro Torres PH, Limaverde Soares Costa Sousa G, Pascutti PG. Structural analysis of the N-terminal fragment of the antiangiogenic protein endostatin: a molecular dynamics study. Proteins. 2011;79(9):2684–92.
65.
Van Valckenborgh E, et al. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer. 2002;101(6):512–8.PubMedCrossRef
66.
Vanderkerken K, et al. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196–206.PubMedCrossRef
67.
Alexandrakis MG, et al. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta. 2007;379(1–2):31–5.PubMedCrossRef
68.
Rocks N, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 2008;90(2):369–79.PubMedCrossRef
69.
Bret C, et al. Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment. Exp Hematol. 2011;39:546–57.PubMedCrossRef
70.
Karadag A, Zhou M, Croucher PI. ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin. Blood. 2006;107(8):3271–8.PubMedCrossRef
71.
Hideshima T, et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol. 2001;28(6):607–12.PubMedCrossRef
72.
Giuliani N, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 2002;100(13):4615–21.PubMedCrossRef
73.
Martin SK, et al. Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin Cancer Res. 2006;12(23):6973–7.PubMedCrossRef
74.
Terpos E, et al. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma. 2005;46(12):1699–707.PubMedCrossRef
75.
Fisher LW, et al. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem. 1987;262(20):9702–8.PubMed
76.
Caers J, et al. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol. 2006;132(4):469–77.PubMed
77.
Colla S, et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia. 2005;19(12):2166–76.PubMedCrossRef
78.
Brahimi-Horn MC, Pouyssegur J. Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem Pharmacol. 2007;73(3):450–7.PubMedCrossRef
79.
Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002;16(10):1151–62.PubMedCrossRef
80.
Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15(4):678–85.PubMedCrossRef
81.
Wang GL, et al. Hypoxia-inducible factor 1 is a basic helix–loop–helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92(12):5510–4.PubMedCrossRef
82.
Yoo YG, et al. An essential role of the HIF-1alpha-c-Myc axis in malignant progression. Ann NY Acad Sci. 2009;1177:198–204.PubMedCrossRef
83.
Zundel W, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14(4):391–6.PubMed
84.
Hu Y, et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther. 2009;8(8):2329–38.PubMedCrossRef
85.
Harrison JS, et al. Oxygen saturation in the bone marrow of healthy volunteers. Blood. 2002;99(1):394.PubMedCrossRef
86.
Colla S, et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010;24(11):1967–70.PubMedCrossRef
87.
Asosingh K, et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica. 2005;90(6):810–7.PubMed
88.
Zannettino AC, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005;65(5):1700–9.PubMedCrossRef
89.
Martin SK, et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica. 2010;95(5):776–84.PubMedCrossRef
90.
Maxwell PH, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.PubMedCrossRef
91.
Hatzimichael E, et al. Von Hippel–Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clin Lymphoma Myeloma. 2009;9(3):239–42.PubMedCrossRef
92.
Eischen CM, et al. Disruption of the ARF-Mdm2–p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658–69.PubMedCrossRef
93.
Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem. 1996;65:101–33.PubMedCrossRef
94.
Menssen A, Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA. 2002;99(9):6274–9.PubMedCrossRef
95.
Zhang J, et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009;69(12):5082–90.PubMedCrossRef
96.
Koong AC, et al. Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res. 1994;54(20):5273–9.PubMed
97.
Karashima T, et al. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res. 2003;9(7):2786–97.PubMed
98.
Annunziata CM, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115–30.PubMedCrossRef
99.
Keats JJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131–44.PubMedCrossRef
100.
van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J. 2008;412(3):477–84.PubMedCrossRef
101.
Jung YJ, et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17(14):2115–7.PubMed
102.
Qiao Q, et al. NF-kappaB mediates aberrant activation of HIF-1 in malignant lymphoma. Exp Hematol. 2010;38(12):1199–208.PubMedCrossRef
103.
Nam SY, et al. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-kappaB promotes gastric tumour growth and angiogenesis. Br J Cancer. 2011;104(1):166–74.PubMedCrossRef
104.
Kwon HC, et al. Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer. Cancer Sci. 2010;101(6):1557–61.PubMedCrossRef
105.
D’Amato RJ, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91(9):4082–5.PubMedCrossRef
106.
Vacca A, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(23):5334–46.CrossRef
107.
Rajkumar SV, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050–3.PubMedCrossRef
108.
Richardson PG, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108(10):3458–64.PubMedCrossRef
109.
Lentzsch S, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17(1):41–4.PubMedCrossRef
110.
Lu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009;77(2):78–86.PubMedCrossRef
111.
De Luisi A, et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res. 2011;17(7):1935–46.PubMedCrossRef
112.
Mitra-Kaushik S, et al. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood. 2004;104(3):802–9.PubMedCrossRef
113.
Roccaro AM, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66(1):184–91.PubMedCrossRef
114.
De Vos J, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002;21(44):6848–57.PubMedCrossRef
115.
Munshi NC, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004;103(5):1799–806.PubMedCrossRef
116.
Bao H, et al. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol. 2009;90(2):177–85.PubMedCrossRef
117.
Seckinger A, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 2009;28(44):3866–79.PubMedCrossRef
Metadata
Title
Biological aspects of angiogenesis in multiple myeloma
Authors
Eléonore Otjacques
Marilène Binsfeld
Agnes Noel
Yves Beguin
Didier Cataldo
Jo Caers
Publication date
01-12-2011
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0963-z

Other articles of this Issue 6/2011

International Journal of Hematology 6/2011 Go to the issue

Letter to the editor

Reconstitution of regulatory T cells after autologous transplantation in multiple myeloma

Case Report

Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation

Case Report

Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult

Case Report

Intravascular B-cell lymphoma with hypercalcemia as the initial presentation

Rapid Communication

Co-culture of hematopoietic stem cells with mesenchymal stem cells increases VCAM-1-dependent migration of primitive hematopoietic stem cells

Original Article

Apoptosis induced by ZnPcH1-based photodynamic therapy in Jurkat cells and HEL cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits